Tissue factor production inhibitor
2005
A medicament having production suppressing action of tissue factor, a medicament comprising a LXR ligand as an active ingredient, and angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA), or vascular remodeling after stenting treatment and / or prevention of stenosis or coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina, cardiovascular and cerebrovascular diseases including thromboembolic forming diseases associated with diabetes, rethrombosis after thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, aortic - thromboembolic formation diseases during coronary bypass use, glomerulosclerosis, renal embolism, tumor or a medicament for the treatment and / or prevention of cancer metastasis, medicaments containing LXR ligand as an active ingredient.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI